Terumo BCT, Inc. is a medical technology company headquartered in Lakewood, Colorado, specialising in blood component collection, therapeutic apheresis, and cellular therapy technologies. A subsidiary of Terumo Corporation (TSE: 4543), which was founded in 1921 and is headquartered in Tokyo, Japan, Terumo BCT operates across more than 130 countries and employs over 8,000 people worldwide.
The company's product portfolio addresses a range of clinical needs. The Spectra Optia Apheresis System is used for therapeutic apheresis procedures, including treatment of conditions such as sickle cell disease and therapeutic plasma exchange. The Quantum Flex Cell Expansion System supports cellular therapy manufacturing, including cell expansion for CAR-T therapies.
Terumo BCT's work spans blood banking and transfusion medicine, therapeutic apheresis, and cell manufacturing - areas that sit at the intersection of established clinical practice and emerging biotechnology. The company is active in blood safety initiatives and partners with organisations such as The Leukemia & Lymphoma Society. It also runs a global community education programme called "From the Heart," aimed at educating and empowering communities around blood and cell health.